Intro.qxp 5/10/07 16:33 Page 4
Introduction
Next, the pharmacotherapy of ovarian stimulation with follitropin beta is that of maximizing treatment outcomes in assisted reproductive
reviewed. In this chapter, authored by Henk Jan Out, MD, the technologies while minimizing the risks associated with multiple
development of recombinant follicle-stimulating hormone (rFSH) is pregnancies. Richard Scott, MD, identifies these risks and reviews the
discussed (see pages 13–16). Dr Out also highlights the benefits of rFSH,
and offers a look forward into some of the genetic technologies that
may contribute to treatment advances for infertile couples in the future.
…providing a rare look at the
In their chapter, Samuel Pang, MD, and Michael Kettel, MD, describe
technological developments that
the simplification of infertility treatment processes through the use
have affected clinical practice and a
of technological advances—specifically the pen delivery system—
for the administration of gonadotropins for patients undergoing
glimpse of how patient demographics
controlled ovarian stimulation for in vitro fertilization (IVF) or ovulation
have changed since then.
induction (see pages 20–22). These two reproductive endocrinologists
draw from their clinical experience as investigators in the two
registration trials that examined ease of use and patient understanding success rates of single-embryo transfer. He brings a scientific review as
when using a pen delivery system to self-administer follitropin beta. That well as his clinical experience into the discussion to emphasize the need
experience, along with their subsequent clinical practice using the for individualized care and patient selection when considering this
device, makes this an enlightening chapter, complemented by the treatment option for infertile patients.
following report of the results of patient and healthcare provider
satisfaction surveys with the Follistim Pen in everyday clinical practice, In the concluding chapter, we are honored to have Howard Jones, MD,
written by myself and my co-authors Drew Moffitt, MD, and Ms Rochelle share his views on the immediate and distant future of fertility treatment
Orr (see pages 23–26). (see pages 30–32). First, though, Dr Jones takes us back to the start of
assisted reproductive technology in the US, providing a rare look at the
technological developments that have affected clinical practice and a
…one of the most important issues
glimpse of how patient demographics have changed since then. He then
faced by reproductive medicine today is
brings us beyond today to a future where he proposes a new era in
reproductive medicine.
that of maximizing treatment outcomes
in assisted reproductive technologies
We are delighted to offer you ‘10 Years of Follistim
®
Branded Products
and Beyond,’ and sincerely hope that it imparts scientific fodder for
while minimizing the risks associated
consideration and discussion in this quickly evolving field. ■
with multiple pregnancies.
Acknowledgments
We would like to acknowledge the following Organon USA Inc. employees
The next chapter, on single-embryo transfer (see pages 27–29), addresses who have contributed writing and editorial assistance to this publication:
one of the most important issues faced by reproductive medicine today: Ana Garcia, Edna V Greig, MSc, and Reeti Sethi, PharmD.
Correspondence
Organon USA Inc., 56 Livingston Avenue, Roseland, NJ, USA
Tel: +1 973 324 6987
Fax: +1 973 325 4699
E-mail: m.mahony@organonusa.com
4 FERTILITY TREATMENT REVIEW
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35